Bridgebio Pharma sells rare pediatric disease priority review voucher for $110 million

BridgeBio Pharma

13 May 2022 - Entered into a definitive agreement to sell the rare paediatric disease priority review voucher it obtained in February 2021 for $110 million.

BridgeBio Pharma announced today that it has entered into a definitive agreement with an undisclosed purchaser to sell its priority review voucher for $110 million.

Read BridgeBio Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

US , Priority review